Sökning: WFRF:(Iaccarino L)
> (2021) >
Accuracy of Tau Pos...
Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease : A Head-to-Head Comparison against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging
-
- Ossenkoppele, Rik (författare)
- Skåne University Hospital,Vrije Universiteit Amsterdam
-
- Smith, Ruben (författare)
- Skåne University Hospital
-
- Mattsson-Carlgren, Niklas (författare)
- Lund University,Lunds universitet,Klinisk minnesforskning,Forskargrupper vid Lunds universitet,Brain Injury After Cardiac Arrest,WCMM- Wallenberg center för molekylär medicinsk forskning,Medicinska fakulteten,Clinical Memory Research,Lund University Research Groups,WCMM-Wallenberg Centre for Molecular Medicine,Faculty of Medicine,Skåne University Hospital
-
visa fler...
-
- Groot, Colin (författare)
- Vrije Universiteit Amsterdam
-
- Leuzy, Antoine (författare)
- Skåne University Hospital
-
- Strandberg, Olof (författare)
- Skåne University Hospital
-
- Palmqvist, Sebastian (författare)
- Skåne University Hospital
-
- Olsson, Tomas (författare)
- Skåne University Hospital
-
- Jögi, Jonas (författare)
- Skåne University Hospital
-
- Stormrud, Erik (författare)
- Skåne University Hospital
-
Cho, Hanna (författare)
-
Ryu, Young Hoon (författare)
-
- Choi, Jae Yong (författare)
- Korea Institute of Radiological & Medical Sciences (KIRAMS)
-
- Boxer, Adam L. (författare)
- University of California, San Francisco
-
- Gorno-Tempini, Maria L. (författare)
- University of California, San Francisco
-
- Miller, Bruce L. (författare)
- University of California, San Francisco
-
- Soleimani-Meigooni, David (författare)
- University of California, San Francisco
-
- Iaccarino, Leonardo (författare)
- University of California, San Francisco
-
- La Joie, Renaud (författare)
- University of California, San Francisco
-
- Baker, Suzanne (författare)
- Lawrence Berkeley National Laboratory
-
- Borroni, Edilio (författare)
- F. Hoffmann-La Roche AG
-
- Klein, Gregory (författare)
- F. Hoffmann-La Roche AG
-
- Pontecorvo, Michael J. (författare)
- Avid Radiopharmaceuticals, Inc
-
- Devous, Michael D. (författare)
- Avid Radiopharmaceuticals, Inc
-
- Jagust, William J. (författare)
- University of California, Berkeley,Lawrence Berkeley National Laboratory
-
Lyoo, Chul Hyoung (författare)
-
- Rabinovici, Gil D. (författare)
- Lawrence Berkeley National Laboratory,University of California, San Francisco
-
- Hansson, Oskar (författare)
- Lund University,Lunds universitet,Klinisk minnesforskning,Forskargrupper vid Lunds universitet,Clinical Memory Research,Lund University Research Groups,Skåne University Hospital
-
visa färre...
-
(creator_code:org_t)
- American Medical Association (AMA), 2021
- 2021
- Engelska 11 s.
-
Ingår i: JAMA Neurology. - : American Medical Association (AMA). - 2168-6149. ; 78:8, s. 961-971
- Relaterad länk:
-
http://dx.doi.org/10... (free)
-
visa fler...
-
https://jamanetwork....
-
https://lup.lub.lu.s...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Importance: Tau positron emission tomography (PET) tracers have proven useful for the differential diagnosis of dementia, but their utility for predicting cognitive change is unclear. Objective: To examine the prognostic accuracy of baseline fluorine 18 (18F)-flortaucipir and [18F]RO948 (tau) PET in individuals across the Alzheimer disease (AD) clinical spectrum and to perform a head-to-head comparison against established magnetic resonance imaging (MRI) and amyloid PET markers. Design, Setting, and Participants: This prognostic study collected data from 8 cohorts in South Korea, Sweden, and the US from June 1, 2014, to February 28, 2021, with a mean (SD) follow-up of 1.9 (0.8) years. A total of 1431 participants were recruited from memory clinics, clinical trials, or cohort studies; 673 were cognitively unimpaired (CU group; 253 [37.6%] positive for amyloid-β [Aβ]), 443 had mild cognitive impairment (MCI group; 271 [61.2%] positive for Aβ), and 315 had a clinical diagnosis of AD dementia (315 [100%] positive for Aβ). Exposures: [18F]Flortaucipir PET in the discovery cohort (n = 1135) or [18F]RO948 PET in the replication cohort (n = 296), T1-weighted MRI (n = 1431), and amyloid PET (n = 1329) at baseline and repeated Mini-Mental State Examination (MMSE) evaluation. Main Outcomes and Measures: Baseline [18F]flortaucipir/[18F]RO948 PET retention within a temporal region of interest, MRI-based AD-signature cortical thickness, and amyloid PET Centiloids were used to predict changes in MMSE using linear mixed-effects models adjusted for age, sex, education, and cohort. Mediation/interaction analyses tested whether associations between baseline tau PET and cognitive change were mediated by baseline MRI measures and whether age, sex, and APOE genotype modified these associations. Results: Among 1431 participants, the mean (SD) age was 71.2 (8.8) years; 751 (52.5%) were male. Findings for [18F]flortaucipir PET predicted longitudinal changes in MMSE, and effect sizes were stronger than for AD-signature cortical thickness and amyloid PET across all participants (R2, 0.35 [tau PET] vs 0.24 [MRI] vs 0.17 [amyloid PET]; P <.001, bootstrapped for difference) in the Aβ-positive MCI group (R2, 0.25 [tau PET] vs 0.15 [MRI] vs 0.07 [amyloid PET]; P <.001, bootstrapped for difference) and in the Aβ-positive CU group (R2, 0.16 [tau PET] vs 0.08 [MRI] vs 0.08 [amyloid PET]; P <.001, bootstrapped for difference). These findings were replicated in the [18F]RO948 PET cohort. MRI mediated the association between [18F]flortaucipir PET and MMSE in the groups with AD dementia (33.4% [95% CI, 15.5%-60.0%] of the total effect) and Aβ-positive MCI (13.6% [95% CI, 0.0%-28.0%] of the total effect), but not the Aβ-positive CU group (3.7% [95% CI, -17.5% to 39.0%]; P =.71). Age (t = -2.28; P =.02), but not sex (t = 0.92; P =.36) or APOE genotype (t = 1.06; P =.29) modified the association between baseline [18F]flortaucipir PET and cognitive change, such that older individuals showed faster cognitive decline at similar tau PET levels. Conclusions and Relevance: The findings of this prognostic study suggest that tau PET is a promising tool for predicting cognitive change that is superior to amyloid PET and MRI and may support the prognostic process in preclinical and prodromal stages of AD.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Neurologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Neurology (hsv//eng)
Publikations- och innehållstyp
- art (ämneskategori)
- ref (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Ossenkoppele, Ri ...
-
Smith, Ruben
-
Mattsson-Carlgre ...
-
Groot, Colin
-
Leuzy, Antoine
-
Strandberg, Olof
-
visa fler...
-
Palmqvist, Sebas ...
-
Olsson, Tomas
-
Jögi, Jonas
-
Stormrud, Erik
-
Cho, Hanna
-
Ryu, Young Hoon
-
Choi, Jae Yong
-
Boxer, Adam L.
-
Gorno-Tempini, M ...
-
Miller, Bruce L.
-
Soleimani-Meigoo ...
-
Iaccarino, Leona ...
-
La Joie, Renaud
-
Baker, Suzanne
-
Borroni, Edilio
-
Klein, Gregory
-
Pontecorvo, Mich ...
-
Devous, Michael ...
-
Jagust, William ...
-
Lyoo, Chul Hyoun ...
-
Rabinovici, Gil ...
-
Hansson, Oskar
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Neurologi
- Artiklar i publikationen
-
JAMA Neurology
- Av lärosätet
-
Lunds universitet